Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradley Nelson

Podiatrist Clinton, OK Doctor of Podiatric Medicine

NPI 1285634469 CMS profile 827491

207 S 30Th Street, Clinton, OK 73601

Open in the dashboard

General payments

$3,227

43 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradley Nelson of Clinton, OK is reported in the CMS Open Payments database as having received $3,227 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,656 10
2024 General $248 7
2023 General $173 7
2022 General $478 8
2021 General $606 9
2020 General $27 1
2019 General $41 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Nelson
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Bradley Nelson were reported at $1,656. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Bradley Nelson Podiatrist median Middle half National median
2019 $41 $196 $72–$601 $163
2020 $27 $118 $38–$335 $114
2021 $606 $169 $57–$573 $132
2022 $478 $220 $74–$782 $149
2023 $173 $208 $71–$635 $160
2024 $248 $237 $87–$681 $164
2025 $1,656 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ConvaTec Inc. $1,633 9 payments
  2. Organogenesis Inc. $1,078 18 payments
  3. Stryker Corporation $310 9 payments
  4. restor3d, inc. $121 4 payments
  5. Treace Medical Concepts, Inc. $44 1 payment
  6. Smith+Nephew, Inc. $27 1 payment
  7. DePuy Synthes Sales Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,992 40 payments
  2. Travel and Lodging $1,236 3 payments
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $1,633 9 payments
  2. Puraply $885 13 payments
  3. AUGMENT INJECTABLE $201 3 payments
  4. Affinity $116 2 payments
  5. Puraply Antimicrobial $77 3 payments
  6. LAPIPLASTY SYSTEM $44 1 payment
  7. ALLOWRAP $41 1 payment
  8. ALLOGRAFT $41 1 payment
  9. ORTHOLOC 2 LAPIFUSE $36 2 payments
  10. EASYFUSE $36 2 payments
  11. Other $141 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

485

Median for Podiatry: 160

Drug cost

$7,195

Median for Podiatry: $2,368

Branded share of claims

21.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort Brand 30 $1,574
Gabapentin Generic 78 $1,006
Pregabalin Generic 41 $800
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 11 $690
Doxycycline Hyclate Generic 44 $673
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 63 $673
Duloxetine Hcl Generic 55 $480
Diclofenac Sodium Generic 39 $389
Ammonium Lactate Generic 14 $235
Naproxen Generic 39 $190

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$2,534,650

Of which drugs: $1,898,138

Medicare patients

786

Average age 76

Services billed

5,894

413 women, 373 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 50%
Ischemic heart disease 43%
Heart failure 28%
Chronic kidney disease 27%
Depression 25%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record